Reports Q4 revenue $369.7M, consensus $330.43M. "2022 was another successful year for Insulet as we delivered strong revenue growth and advanced our strategic priorities," said Jim Hollingshead, President and Chief Executive Officer. "We entered 2023 with significant momentum and expect to further strengthen our foundation for long-term sustainable growth. We are excited about the commercial launch of Omnipod 5, which is a transformative technology offering users award-winning innovation and improved outcomes and quality of life. We are proud of all we have accomplished and the entire Insulet team is focused on building on our success and furthering our mission to improve the lives of people with diabetes."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PODD:
- DexCom selloff on Apple article should be bought, says Oppenheimer
- Insulet acquires assets of Automated Glucose Control for $25M
- Insulet acquires insulin pump patents from Bigfoot Biomedical for $25M
- Insulet initiated with a Peer Perform at Wolfe Research
- Insulet price target raised to $245 from $238 at Barclays
